{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:24:57Z","timestamp":1649075097870},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.acuro.2017.02.005","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T23:00:48Z","timestamp":1499209248000},"page":"152-162","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eficacia de la toxina botul\u00ednica A para el tratamiento del s\u00edndrome de dolor vesical: una revisi\u00f3n sistem\u00e1tica"],"prefix":"10.1016","volume":"42","author":[{"given":"D.C.","family":"Ochoa Vargas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.A.","family":"Garc\u00eda Perd\u00f3mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2017.02.005_bib0085","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/pr.56.4.4","article-title":"Pharmacology of the lower urinary tract: Basis for current and future treatments of urinary incontinence","volume":"56","author":"Andersson","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.acuro.2017.02.005_bib0090","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.juro.2011.03.064","article-title":"AUA guideline for the diagnosis and treatment of interstitial cystitis\/bladder pain syndrome","volume":"185","author":"Hanno","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.02.005_bib0095","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.juro.2011.10.040","article-title":"Comparison of an interstitial cystitis\/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study","volume":"187","author":"Konkle","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.02.005_bib0100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.juro.2007.10.032","article-title":"Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup","volume":"179","author":"Giannantoni","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.02.005_bib0105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.eururo.2013.04.035","article-title":"The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development","volume":"64","author":"Engeler","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.02.005_bib0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.acuro.2015.12.011","article-title":"Hidrodistensi\u00f3n bajo anestesia m\u00e1s inyecci\u00f3n de Onabotulinumtoxin A en pacientes con s\u00edndrome de dolor vesical refractario a tratamiento conservador","volume":"40","author":"Lorenzo","year":"2016","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2017.02.005_bib0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000087173","article-title":"Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis","volume":"75","author":"Kuo","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.acuro.2017.02.005_bib0120","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","article-title":"Botulinum toxin a has antinociceptive effects in treating interstitial cystitis","volume":"64","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2017.02.005_bib0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.juro.2012.02.912","article-title":"Randomized controlled trial for efficacy of botulinum toxin type A in treament of patients suffering bladder pain syndrom\/intertitial cystitis with Hunners\u2019 lesions: Preeliminary results","volume":"187","author":"Kasyan","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.02.005_bib0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00192-013-2267-8","article-title":"A multicentre, prospective, randomised, double-blind study to measure the treatmenteffectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis\/bladder pain syndrome","volume":"25","author":"Manning","year":"2014","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.acuro.2017.02.005_bib0135","article-title":"A randomized controlled trial of bacillus Calmette-Guerin and botulinum toxin-A for the treatment of refractory interstitial cystitis","volume":"2","author":"El\u2013Bahnasy","year":"2009","journal-title":"UIJ"},{"key":"10.1016\/j.acuro.2017.02.005_bib0140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/nau.22760","article-title":"Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment - a prospective, multicenter, randomized, double-blind placebo-controlled clinical trial: Intravesical BoNT","volume":"35","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuro.2017.02.005_bib0145","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2017.02.005_bib0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4081\/aiua.2014.2.126","article-title":"Painful bladder syndrome\/interstitial cystitis: Aetiology, evaluation and management","volume":"86","author":"Rourke","year":"2014","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.acuro.2017.02.005_bib0155","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.eururo.2012.03.031","article-title":"Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder","volume":"62","author":"Ikeda","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.02.005_bib0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2010.02.031","article-title":"Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome\/interstitial cystitis","volume":"58","author":"Pinto","year":"2010","journal-title":"Eur Urol"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480617300682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480617300682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T16:50:27Z","timestamp":1530031827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480617300682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0210480617300682"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2017.02.005","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eficacia de la toxina botul\u00ednica A para el tratamiento del s\u00edndrome de dolor vesical: una revisi\u00f3n sistem\u00e1tica","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2017.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}